The authors retrospectively analyzed the angiographic findings performed in 17 cases with central neurocytoma to document the angiographic characteristics and suggested the origin of tumor based on the angiographic findings. Their medical records and radiological investigations were reviewed and cerebral angiographies were thoroughly examined in arterial, capillary, and venous phases. In ten cases, marked or moderate tumor staining was found whereas the staining was either scanty or absent in seven cases. In the ten cases showing marked or moderate tumor staining, the feeding vessels were originated from the ipsilateral carotid and/or vertebro-basilar system. In the venous phase, the ipsilateral thalamostriate vein, tortuous and enlarged, was elevated, and the internal cerebral vein was depressed. Thus, the venous angle of the ipsilateral side was widened at an irregular contour. Based on the characteristic displacement and the increased size of the associated venous system, it is suggested that the central neurocytoma might originate from a neuronal cell mass of the subependymal zone located on the floor of the lateral ventricle around the foramen of Monro rather than from the septum pellucidum.
Adult ; Angiography/*methods ; Carotid Arteries/pathology ; Central Nervous System Neoplasms/*diagnosis/*pathology ; Cerebral Ventricle Neoplasms/*diagnosis/*pathology ; Female ; Human ; Magnetic Resonance Imaging ; Male ; Models, Anatomic ; Neurocytoma/*diagnosis/*pathology ; Neurons/metabolism ; Retrospective Studies

OBJECTIVES: To determine the presentation, incidence, and risk factors of seizures in patients treated for brain tumors. METHODS: One hundred patients who consecutively underwent a craniotomy for the treatment of supratentorial brain tumors were assessed. The pathologies of the patients enrolled in the study included glioma (n=56), meningioma (n=31), metastatic brain tumor (n=7), primary central nervous system lymphoma (n=4), and central neurocytoma (n=2). Anti-epileptic drugs (AEDs) were administered to all patients for up to six months after the surgery. Pre-defined variables for outcome analysis included tumor grade and location, extent of tumor resection, number of seizures, age at tumor diagnosis, adjuvant therapy, medication and radiological abnormalities. RESULTS: Thirty patients (30%) presented at least a single episode of seizure at the time of admission. Five of these patients (16.7%) developed the seizure during the follow-up period. Newly developed seizure was noticed in six out of seventy patients (8.6%) without prior seizure. Histopathology was malignant gliomas in 10 and supratentorial meningioma in one. Early seizure developed only in two patients. CONCLUSION: Compared with patients without seizure, patients with seizure at the time of admission showed younger age (p=0.003), a higher portion of low-grade glioma (p=0.001), tumor location in the frontal and temporal lobes (p=0.003) and cortical involvement (p=0.017). Our study suggestes that tumor progression is considered a significant risk factor for seizure development in glioma patients.
Brain Neoplasms* ; Brain* ; Central Nervous System ; Craniotomy ; Diagnosis ; Follow-Up Studies ; Glioma ; Humans ; Incidence ; Lymphoma ; Meningioma ; Neurocytoma ; Pathology ; Risk Factors ; Seizures* ; Temporal Lobe

Antigens, Nuclear ; metabolism ; Cordotomy ; methods ; Diagnosis, Differential ; Ependymoma ; metabolism ; pathology ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nerve Tissue Proteins ; metabolism ; Neurocytoma ; metabolism ; pathology ; surgery ; Oligodendroglioma ; S100 Proteins ; metabolism ; Spinal Cord Neoplasms ; metabolism ; pathology ; surgery ; Synaptophysin ; metabolism

Animals ; Antigens, Nuclear ; metabolism ; Basic Helix-Loop-Helix Transcription Factors ; metabolism ; Biomarkers, Tumor ; metabolism ; Central Nervous System Neoplasms ; metabolism ; pathology ; Diagnosis, Differential ; Ependymoma ; metabolism ; pathology ; Humans ; Immunohistochemistry ; methods ; Intermediate Filament Proteins ; metabolism ; Medulloblastoma ; metabolism ; pathology ; Mucin-1 ; metabolism ; Nerve Tissue Proteins ; metabolism ; Nestin ; Neurocytoma ; metabolism ; pathology ; Oligodendrocyte Transcription Factor 2 ; Oligodendroglioma ; metabolism ; pathology